Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 18 |
| Active Pipeline (Recruiting Now) | 11 (5) |
| Completed vs Stopped Early | 3 / 2 (11.1%) |
| Median Closed Actual Enrollment | 45 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07280585 | STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University of Cologne Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.